74 results about "Kappa-Carrageenan" patented technology

Gelatin-free capsule for use in oral administration of medicines, cosmetic or bath applications, or dietary supplements can be prepared from compositions comprisinga) 8-50% by weight of water-dispersible or water-soluble plasticizer,b) 0.5 to 12% by weight kappa-carrageenan,c) 0 to 60% dextrins, andd) 1% to 95% by weight water,with the kappa-carrageenan comprising at least 50% by weight of all gums forming or contributing to formation of thermoreversible gels in the composition. A capsule for oral administration or cosmetic application may comprise a fill material to be administered to a patient or subject and a capsule, the capsule comprising an aqueous based film comprisinga) water-dispersible or water-soluble plasticizer, andb) carrageenan,with the carrageenan comprising at least 50% or 75% by weight of kappa-carrageenan, and the carrageenan comprising at least 50% or 75% by weight of all gums which form or contribute to the formation of thermoreversible gels. A process for forming the capsules may comprise heating the composition, casting or extruding the composition into a film, gelling the composition by cooling, associating a fill material with the gelled composition (usually as a film) and sealing the film about the fill material.

A film-forming hydrocolloid composition comprising kappa carrageenan, iota carrageenan, a bulking agent, plasticizer and water is described. The ratio of bulking agent to total carrageenan is from about 1:1 to 20:1. Kappa carrageenan is present in an amount of less than or equal to 50% by weight of total carrageenan present. To form the composition, all dry materials are mixed and added to a heated mixture of all liquid materials. The final mixture is heated until a composition free of particulate materials is formed. The formed composition can be cast or extruded into ribbons, films, sheets, tubes or the like, for encapsulating wet or dry materials including medicinal dosage forms, nutritional supplements, cosmetics, bath oils and gels, and paint balls.

A cartridge for an e-vaping device includes an ethanol-free gel formulation. The ethanol-free gel formulation includes a vapor former, water, and a biopolymer. The biopolymer may be included in an amount ranging from about 0.01% by weight based on the weight of the ethanol-free gel formulation to about 2.0% by weight based on the weight of the ethanol-free gel formulation. The biopolymer may be one or more of agar, kappa carrageenan, gelatin, sodium alginate, gellan gum, pectin, and combinations thereof. The cartridge also includes a heater configured to heat liquid from the gel formulation to a temperature sufficient to release a liquid/semi-liquid component from the gel, which component thereupon forms a vapor.

An integrated method is developed to utilise to a maximum extent the fresh biomass of seaweeds such as Kappaphycus alvarezii that can be crushed to release sap and where the sap is useful as a potent liquid fertilizer after suitable treatment with additives and dilution while the residue is a superior raw material for extraction of kappa-carrageenan, thereby enhancing the value of the seaweed. Other advantages of the invention include a reduced drying time and drying area to obtain the raw material for kappa-carrageenan production in dry and storable form, a reduced cost of transporting and storing this raw material because of its lesser bulk, easier handling due to its free flowing granular nature, and its direct use for gel preparation in certain applications.

Disclosed is a carrageenan composition comprising sodium, potassium, calcium and magnesium.

The present invention relates to a process for treating precipitated carrageenan, comprising the steps of (a) treating the precipitated carrageenan with an aqueous treatment solution containing an alkali or a salt, (b) washing the treated precipitated carrageenan in water, and (c) drying the washed precipitated carrageenan.

The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.

The invention discloses a hollow capsule, which comprises the following components in parts by weight: 10 to 30 parts of kappa-carrageenan, 90 to 180 parts of water-soluble crosslinked starch, and 20 to 40 parts of plasticizer. The invention also discloses a preparation of the hollow capsule, which comprises the following steps of: 1) dissolving gum, wherein carrageenan and water-soluble crosslinked starch are stirred, water at a temperature of between 70 and 90 DEG C is added into the mixture, the plasticizer in the amount of the prescription is added and completely dissolved, and the mixture is stirred uniformly; 2) culturing the gum, wherein the gum liquid obtained in the step 1) is cooled to a temperature of between 40 and 45 DEG C, the gum liquid is insulated and stood for 30 to 60 minutes, and the gum liquid is put into a gum soaking tank; and 3) soaking the gum, wherein when the temperature of the gum liquid in the gum soaking tank is cooled to 35 DEG C, operations of gum soaking, drying, shell pulling out, cutting and buckling are automatically carried out through a capsule template. According to the hollow capsule disclosed by the invention, the transparency and toughness are remarkably improved, the friability is remarkably reduced, and the product yield is greatly increased.

The invention discloses a pseudoalteromonas WZU4771, the strain is preserved in China General Microbiological Culture Collection Center, and preservation number is CGMCCNO. 3407. The kappa-carrageenan hydrolase produced by the pseudoalteromonas WZU4771 can hydrolyze kappa-carrageenan, and finally kappa-new cara tetrasaccharide sulphate is obtained.

The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents.

The present invention relates to a solid composition for topical application, which is free of fillers, containing, in an aqueous phase, less than 20% of the total weight of the composition of a hydrophilic gelling system comprising the combination of at least 2% by weight of kappa-carrageenan, relative to the total weight of the composition, and at least one hydrocolloid chosen from xanthan gum and cellulose derivatives which are soluble in hot water. The solid composition obtained is, in the absence of oil, transparent or translucent and can be applied directly to a support. This composition is generally in the form of tubes, pencils or bars and can constitute solid products to care for and/or treat the skin, the scalp, the hair or mucous membranes, to make up the skin and/or keratin fibres such as the eyelashes and the hair, and to style and/or shape keratin fibres, and in particular the hair.

A dentifrice composition which comprises (A) heavy calcium carbonate having a mean particle diameter of 5 to 15 m, (B) water-insoluble inorganic granules having a collapse strength of 10 to 200g/granule, a mean particle diameter of 50 to 150 m, and a difference of 100 m or below between 90% particle diameter and mean particle diameter, and (C) a water-soluble polymeric material comprising at least one member selected from Group (a) and at least one member selected from Group (b) at a (b)/(a) mass ratio of 0.25 to 3, Group (a): sodium alginate, sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, Xanthomonas campestris, lambda-carrageenan, and straight-chain sodium polyacrylate, and Group (b): gellan gum, agar, kappa-carrageenan, iota-carrageenan, gelatin, pectin, and crosslinked sodium polyacrylate, and which has a total content of (a) and (b) of 0.5 to 1.5% by mass based on the whole of the composition.

The invention discloses kappa-carrageenase, a gene encoding the same and an application of kappa-carrageenase. The cloned kappa-carrageenase precursor gene car 30 of P.carrageenovora ASY5 is transformed into E. coli, a recombinant bacterium producing recombinant kappa-carrageenase is obtained, and the suitable temperature and pH of the recombinant kappa-carrageenase are 45 DEG C and 6.5; after heat preservation at 40 DEG C for 30 min, the remnant enzyme activity is 80.0% or higher, the recombinant kappa-carrageenase is treated for 60 min in a buffer solution with pH being 6.5-7.5, and the enzyme activity can still remain 50.0% or higher. The recombinant vector containing the kappa-carrageenase gene car 30 is constructed, heterologous expression is realized, and a good foundation is provided for industrialized production and application of the enzyme. The expressed kappa-carrageenase has a better degradation effect on kappa-carrageenan, kappa-carrageenan is degraded into disaccharide, tetrasccharide and the like, and the kappa-carrageenase can be applied to preparation of antibacterial agents, antiviral agents, immunomodulators, antioxidants and the like.

The invention discloses egg puddings. The egg puddings are prepared from, by weight, 30-50 parts of yolk fluid, 15-30 parts of whole milk powder, 10-15 parts of white granulated sugar, 5-10 parts of condensed milk, 0.4-2.0 parts of konjac fine powder, 0.2-0.5 part of kappa carrageenan, 0.04-1.0 part of potassium chloride and 140-180 parts of water. The egg puddings are smooth and delicate in taste, elastic in texture, strong in egg aroma, rich in nutrition, portable and free of preservatives and sweetening agents, the shelf life of the egg puddings is prolonged, defects of liquid-solid separation and collapse in long-term storage are improved, and technical simplicity in processing, low cost and suitableness for batch production are realized.

The invention discloses an insect-preventing fountain solution containing a kappa-carrageenan-amorophophallus konjac compound. The insect-preventing fountain solution comprises the following raw materials in part by weight: 70-85 parts of deionized water, 10-15 parts of kappa-carrageenan, 6-10 parts of amorophophallus konjac, 3-6 parts of tea polyphenol, 2-5 parts of sulfated caster oil, 1-3 parts of sorbitol, 3-6 parts of a pH regulator, 1-3 parts of fatty alcohol-polyoxyethylene ether, 1-3 parts of a polyether modified silicone defoamer, and 2-4 parts of an insect-preventing additive. Kappa-carrageenan and amorophophallus konjac are compounded to form a compound, and the compound as a hydrophilic film former improves the water film persistence, so that the fountain solution has high wettability and permeability when used; kappa-carrageenan- amorophophallus konjac-tea polyphenol microspheres slow release of tea polyphenol during the using process of the fountain solution, so that the oxidation resistance of tea polyphenol is improved greatly, and the using stability of the fountain solution is ensured; and besides, the fountain solution can achieve the effect of insect prevention, printed image-text is clear, the color is restored, the requirement of printing production is met, and the produced fountain solution is fragrant and pleasant in smell, environment-friendly, nontoxic, and harmless to the human body.

The invention relates to milky tea with the effect of improving the eyesight, which belongs the field of traditional Chinese medicine health-care products. The milky tea is characterized by mainly comprising the following ingredients in proportion by weight: 100-120 of semen cassiae, 80-100 of medlar, 50-100 of chrysanthemum, 2-4 of water, 0.2-0.6 of honey, 30-45 of plant oil of beta-carotene, 0.2-0.8 of ethylene diamine tetraacetic acid, 0.3-0.5 of kappa-carrageenan, 100-120 of glyceryl monostearate, 0.05-0.09 of maltol, 0.02-0.05 of cinnamaldehyde, 30-50 of palmkerneloil, 2-5 of coconut powder, and the like. Medical essences and milky tea are mixed in the invention, and an instant formula is adopted to overcome the defects that effective constituents of bagged tea can be dissolved out after long-time steeping. The milky tea uses the palmkerneloil and the coconut powder to replace vegetable fat powder, does not generate trans fatty acid, has no harm after long-time drinking and maintains the taste.

The preparation process of sulfogalacto oligose with antitumor activity includes compounding kappa-carrageenan substrate, adding kappa-carrageenan enzyme powder for reaction, boiling water bath heating to deactivating enzyme, centrifuging to eliminate enzymolyzed resistance segment, ethanol precipitaition to collecting soluble enzymolyzed oligose, concentration, drying, sulfonating to form derivative, repeated ethanol washing, vacuum filtering and drying. The present invention features the kappa-carrageenan enzyme marine microbe produces, and the themical modification of the enzymolyzed oiligose after concentration and drying. The combination of enzymolysis degrading and chemical modification results in simple preparation process, high yield of product, stable quality and no damage of active radical, and the prouduct has antitumor activity and latent capacity of developing antitumor medicine.

The invention discloses a UV quick adhesive fountain solution containing a kappa-carrageenan-konjac gum compound. The UV quick adhesive fountain solution containing the kappa-carrageenan-konjac gum compound is composed of the following raw materials in parts by weight: 70 to 85 parts of deionized water, 10 to 15 parts of kappa-carrageenan, 6 to 10 parts of konjac gum, 3 to 6 parts of tea polyphenol, 2 to 5 parts of turkey red oil, 1 to 3 parts of sorbitol, 3 to 6 parts of pH regulator, 1 to 3 parts of iso-tridecanol polyoxyethylene ether, 1 to 2 parts of polyether defoamer, and 0.5 to 1 part of aluminum-zirconium coupling agent. According to the fountain solution, the kappa-carrageenan and the konjac gum are compounded to be used as a hydrophilic film-forming agent through which the durability of a water film can be improved, and as a result, the fountain solution is high in wettability and permeability during use; kappa-carrageenan-konjac gum-tea polyphenol microspheres have the characteristics of being small in average particle size and slow to release tea polyphenol, so that the tea polyphenol can be slowly released during the use of the fountain solution, and as a result, the oxidation resistance of the tea polyphenol can be greatly improved, and the use stability of the fountain solution can be ensured.

The invention provides a food product comprising a gelled water-based shell and a liquid centre characterized in that the water-based shell contains a mixture of kappa carrageenan and iota carrageenan in an amount sufficient to provide a gel texture, the relative proportions of kappa carrageenan and iota carrageenan being 50 to 95% by weight kappa carrageenan and 5 to 50% by weight iota carrageenan based on the sum of the weights of kappa and iota carrageenan. The shell avoids the use of gelatin and has improved properties in terms of appearance, texture and ease of manufacture.

The invention discloses an alcohol-free fountain solution containing composite buffering systems. The alcohol-free fountain solution is composed of, by weight, 70-85 parts of deionized water, 10-15 parts of kappa-carrageenan, 6-10 parts of konjac glucomannan, 3-6 parts of tea polyphenol, 2-5 parts of Turkey red oil, 1-3 parts of sorbitol, 3-6 parts of the composite buffering systems, 1-3 parts of alkylphenol ethoxylates and 1-2 parts of sorbitol fatty acid esters. According to the alcohol-free fountain solution, the kappa-carrageenan and the konjac glucomannan are compounded to serve as a hydrophilic film forming agent, so that the durability of a water film is improved, and the fountain solution has good wetting performance and permeability in the using process. Kappa-carrageenan-konjac glucomannan- tea polyphenol microballoons have the characteristics of low average grain sizes and slow tea polyphenol release, and release of the tea polyphenol is delayed during usage of the fountain solution, so that the oxidation resistance of the tea polyphenol is greatly improved, and the stability of usage of the fountain solution is guaranteed. The alcohol-free fountain solution obtained by compounding two buffering systems has excellent buffering tolerance performance and can obviously improve the quality of printing products, and the printing efficiency is improved.

The invention discloses an egg white protein-carrageenan composite film and a preparation method and application thereof. The preparation method comprises the following steps: dissolving kappa-carrageenan in deionized water, performing stirring until no bubbles and then adding egg white protein and glycerin, adjusting a pH value, performing even stirring, performing heating in a water bath at 60 DEG C for 30 min, performing ultrasonic degassing for 10 min, slowly performing even stirring, performing cooling at room temperature for 1 h, performing drying at 40 DEG C until a constant weight of afilm, and performing balancing in a 53% relative humidity environment for 24 h to obtain the egg white protein-carrageenan composite film. The carrageenan and egg white protein are compounded to forma film, disadvantages of protein-based edible films and carrageenan-based edible films are improved, and an application range of edible films is expanded. Preparation process parameters are optimized, the composite film has excellent performance, operability is strong, and the popularization and application is conducive.

The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.